PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19
A Phase 2 Double-blind, Randomized Study to Evaluate the Antiviral Activity, Safety, and Efficacy of Orally Administered PBI-0451(Pomotrelvir) Compared With Placebo in Nonhospitalized Symptomatic Adults With COVID-19
Sponsor: Pardes Biosciences, Inc.
Terminated
Interim analysis concluded primary endpoint was not met
A PHASE2 clinical study on COVID-19, this trial is terminated or withdrawn. The trial is conducted by Pardes Biosciences, Inc. and has accumulated 8 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Jan 2025 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2023 — Apr 2023 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pardes Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .